Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study

European Journal of Neurology

Volumn 19, Issue 3, 2012, Pages 417-425

  Rueda Clausen, C F ^a   Cordoba Porras A ^b   Bedoya, G ^b   Silva, F A ^a   Zarruk, J G ^a   Lopez Jaramillo P ^c   Villa, L A ^b  

^a FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c Research Institute of the Fundacion Oftalmologica de Santander FOSCAL   (Colombia)

Author keywords

Association; Asymmetric dimethylarginine; Hispanic; Hyperhomocysteinemia; Stroke

Indexed keywords

HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CASE CONTROL STUDY; COLOMBIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISPANIC; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; ARGININE; CASE-CONTROL STUDIES; COLOMBIA; FEMALE; HISPANIC AMERICANS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE;

EID: 84856892593     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03534.x     Document Type: Article

References (33)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the american heart association statistics committee and stroke statistics subcommittee. Circulation 2008; 117: e25-e146.
2. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke; a journal of cerebral circulation 2003; 34: 1258-1261.
3. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010; 208: 518-523.
4. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (adma): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007; 45: 1683-1687.
5. Krzyzanowska K, Mittermayer F, Krugluger W, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006; 189: 236-240.
6. Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with alzheimer's disease. Neurobiol Aging 2003; 24: 903-907.
7. Khan U, Hassan A, Vallance P, Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-413.
8. Ilhan N, Seckin D, Ilhan N, Ozbay Y. Abnormal asymmetric dimethylarginine/nitric oxide balance in patients with documented coronary artery disease: relation to renal function and homocysteine. J Thromb Thrombolysis 2007; 23: 205-211.
9. Ziegler S, Mittermayer F, Plank C, Minar E, Wolzt M, Schernthaner GH. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 2005; 90: 2175-2178.
10. Kumagai H, Sakurai M, Takita T, et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48: 797-805.
11. Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin e, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate ckd. Am J Kidney Dis 2009; 53: 41-50.
12. Bushnell CD. Stroke and the female brain. Nat Clin Pract 2008; 4: 22-33.
13. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (adma) determination in human serum. J Chromatogr 2005; 828: 97-102.
14. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65years. Circulation 1995; 91: 2596-2604.
15. Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 1999; 8: 156-160.
16. Bazzano LA, Gu D, Reynolds K, et al. Alcohol consumption and risk for stroke among chinese men. Ann Neurol 2007; 62: 569-578.
17. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the framingham study. Ann Intern Med 1999; 131: 352-355.
18. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke; a journal of cerebral circulation 1990; 21: 572-576.
19. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke; a journal of cerebral circulation 2000; 31: 1069-1075.
20. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke; a journal of cerebral circulation 1994; 25: 1924-1930.
21. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the third national health and nutrition examination survey. Am Heart J 2000; 139: 446-453.
22. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94: 907-915.
23. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
24. Paroni R, Fermo I, Fiorina P, Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 2005; 28: 389-394.
25. Doshi S, McDowell I, Goodfellow J, et al. Relationship between s-adenosylmethionine, s-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 2005; 54: 351-360.
26. Garcia RG, Perez M, Maas R, Schwedhelm E, Boger RH, Lopez-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (adma) in metabolic syndrome. Int J Cardiol 2007; 122: 176-178.
27. Maas R, Boger RH, Schwedhelm E, et al. Plasma concentrations of asymmetric dimethylarginine (adma) in colombian women with pre-eclampsia. JAMA 2004; 291: 823-824.
28. Stuhlinger MC, Stanger O. Asymmetric dimethyl-l-arginine (adma): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6: 3-14.
29. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (adma) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383-388.
30. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-430.
31. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and alzheimer disease in northern ireland. Stroke; a journal of cerebral circulation 2002; 33: 2351-2356.
32. Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1467-1472.
33. Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in latin america. J Hypertens 2008; 26: 1886-1889.